Related Experiment Video
Updated: May 7, 2026
07:12
Time-resolved Förster Resonance Energy Transfer Assays for Measurement of Endogenous Phosphorylated STAT Proteins in Human Cells
Published on: September 9, 2021
Targeting the tumor microenvironment: JAK-STAT3 signaling
Eirini Bournazou1, Jacqueline Bromberg
1Department of Medicine; Memorial Sloan-Kettering Cancer Center (MSKCC); New York, NY USA.
JAK-STAT
|September 24, 2013
Summary
Targeting the JAK-STAT3 pathway impacts tumor microenvironment and immunity. Therapies targeting this pathway may enhance anti-cancer responses by modulating tumor-extrinsic effects and immune suppression.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Persistent Janus Kinase-Signal Transducer and Activator of Transcription 3 (JAK-STAT3) signaling drives tumorigenesis through intrinsic and extrinsic mechanisms.
- STAT3 influences tumor survival, metastasis, and immune evasion by regulating cytokine signaling and altering metastatic sites.
Purpose of the Study:
- To review the effects of JAK-STAT3-targeted therapies on the tumor microenvironment.
- To determine if these effects correlate with therapeutic responsiveness, particularly in the context of tumor immunity.
Main Methods:
- Literature review of studies investigating JAK-STAT3-targeted therapies.
- Analysis of the impact of these therapies on tumor-extrinsic factors and the tumor microenvironment.
- Evaluation of the relationship between observed effects and treatment outcomes.
Main Results:
- JAK-STAT3 inhibition can modulate paracrine cytokine signaling within the tumor microenvironment.
- Targeted therapies may reverse immune suppression and enhance anti-tumor immune responses.
- Observed alterations in the tumor microenvironment are linked to improved therapeutic efficacy.
Conclusions:
- Targeting the JAK-STAT3 pathway represents a promising therapeutic strategy for cancer.
- Modulation of the tumor microenvironment and immune response are key mechanisms underlying the efficacy of these therapies.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:22PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...